Skip to main content

Table 1 Variables included in nomograms predicting lymph node invasion at radical prostatectomy in patients with prostate cancer

From: External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer

Nomogram Covariates
Briganti 2019 [7] PSA at diagnosis
Clinical stage on multiparametric MRI
Grade group on MRI-targeted biopsy
Maximum diameter of the index lesion on multiparametric MRI
Percentage of positive cores with clinically significant cancer on systematic biopsy
Briganti 2017 [16] Biopsy Gleason grade group
Clinical stage
Preoperative PSA
Percentage of positive cores with the highest-grade disease
Percentage of positive cores with the lower-grade disease
Briganti 2012§ [17] PSA at diagnosis
Clinical stage
Primary Gleason grade
Secondary Gleason grade
Percentage of positive cores
MSKCC [18] Preoperative PSA
Primary biopsy Gleason grade
Secondary biopsy Gleason grade
Clinical stage
Number of negative cores
Number of positive cores
Partin 2017†† [19] Preoperative PSA (0–4, 4.1–6, 6.1–10 and greater than 10 ng/ml)
Gleason score (5–6, 3 + 4, 4 + 3/8, and 9–10)
Clinical stage (T1c, T2a and T2b/T2c)
Japan PC table‡‡ [20] Preoperative PSA (0–4, 4.1–6, 6.1–8, 8.1–10, and greater than 10 ng/ml)
Gleason score (6, 3 + 4, 4 + 3, and 8–10)
Clinical stage (T1c, T2a, T2b, and T2c)